So statistichkaobrabotka na dobienite podatotsi da se potvrdi deka rezultatitese vo ramkite na spetsifikatsiskite limiti so shto mozhe da sesmeta deka protsesot na tabletiranje e validiran i sposobenkontinuirano da dava proizvod so odnapred predodredenikarakteristiki.MATERIJALI I METODIPredmet na tekovnata validatsija se tri posledovatelniproizvodni serii na Zolpidem 5 mg film-oblozheni tableti.Rezultatite od protsesnite kontroli na tabletnite jadra (prosechnamasa, tsvrstina i visina) kako i rezultatite od kontrolnite testoviza sodrzhina na aktivnata komponenta vo tabletnite jadra sepredmet na statistichka analiza so pomosh na statistichkata alatka- sposobnost na protses (Process capability)Rezultatite od ovaa statistichka evaluatsija se prikazhani vopodole:281Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONSlika 1:prosechnata masa na tabletnite jadra (n=180)Slika 2:tsvrstina na tabletni jadra (n=30)Slika 3: visina na tabletnite jadra (n=30)Slika 4: sodrzhina na Zolpidem tartarate vo tabletnite jadra (n=90)n - broj na analizirani vrednostiZa prikazhuvanje na sposobnost na protsesot (Process capability)najchesto se koristat dva vida na indeksi Cp (indeks na tsentriranjena protses, indeks na potentsijalna sposobnost) i Cpk (indeks napomestuvanje na protses, indeks na izvorednost na protses). Zakvaliteten protses vrednostite na ovie dva indeksi treba da se >1,3. Koga protsesot e perfektno tsentriran Cp= Cpk.Tabela 1:ZAKLUChOKDeskriptivnata statistika se pokazha kako korisna alatka zastatistichka obrabotka na rezultatite od protsesnite kontroli, ikontrolnite testovi, pri tabletiranje so shto se potvrdi dekaprotsesot na tabletiranje na Zolpidem 5 mg film-oblozhenitableti sekogash dava proizvod chij kvalitet odgovara i e vo ramkitena pretkhodno definiranite spetsifikatsi.282Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAposter prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOLITERATURA1. Sanford Bolton, Charles Bon, Pharmaceutical Statistics, Practical and ClinicalApplications (2004)2. WHO Expert Committee on Specifications for Pharmaceutical Preparations(2006)3. British Pharmacopoeia 7.1 (2011)DEVIATION MANAGEMENT IN INTEGRATEDPHARMACEUTICAL QUALITY SYSTEMNada Popstefanova, Marija Davcheva, MiroslavaIlievska, Svetlana Trajkoska DabevskaALKALOID AD, SkopjeINTRODUCTIONIn general terms, a deviation is non-compliance with an establishedstandard. The EU Guide to Good manufacturing Practice (GMP) statesthat any deviation from the approved requirements and proceduresmust be documented and explained. Integrated PharmaceuticalQuality System is to be measured by complaints, deviations, CAPA,changes and inspection observations. Quality Assurance needs to gobeyond measuring failure to maximize value to the organization.GOALInvestigation of failure, deviation and OOS (out of specification) in thepharmaceutical industry is a regulatory requierment. Recording thedeviation and investigating their cause is one step to meet regulatoryrequierments. Correcting the issue based on risk assesment andunderstending of the science as well as ensuring that the correctiveactions are implemented within the appropriate time frame is anotherstep. Fllow - up of the actions to ensure they are completed, effectiveand the fact that no new issues have been introducted is whatcompletes activities. A summary report must be developed, reviewedand approved by the Quality Assurance. Successful approval of devia-tions and OOS, as well as deviation rate is KPI (key performance indi-cator) for assuring overall Integrated Pharmaceutical Quality Systemand proactive approach to continuous quality improvement.METHODSProcess monitoring, Quarterly Review of all deviation reports as wellas Annual product Reviews (APR) are the tools nessesery to ensure thatnegative trends do not develop and that manufacturing processremains under control. Using risk managmement to deal withdeviation provides a consistent frame work for decision-making basedon documentary and scientific records, while also enabling decisionsto be confidently upheld before the regulatory bodies. Riskmanagment tool for classifying and handling deviations is flowchartfor deciding the criticality of deviation.In the example of medical device -X-ray films and concentrated solu-tions for haemodialysis, it is assumed that the process in which thedeviation arose has undergone appropriate risk analysis, so thefollowing are known:>> Failure (deviation) history with assosiated severity assesmentcriteria>> Probaility data for the most commonly occurring failures(deviations);>> Critical points and/or stages in the process;>> A definition of the product's critical quality attributes.>> The metodology witch is employed consists of several phases -analysis phase, classification phase and treatment phase.ANALYSIS PHASEThe aim of this phase is to place the event that has occurred into oneof the pre-established categories. This is done using a detection threebased on a set of questions with yes/no answers, directly directlydefining the category of the event.CLASSIFICATION PHASEHaving followed the strategy, the event is classified into one offollowing categories: incident; non-critical deviation and criticaldeviation.TREATMENT PHASEbased on the category into which the event has been plased, actionare taken as follows:Incident: If the event is classed as an "Incident" is the closed, as the ac-tions required to resolve it are described.Non - critical deviation: The process deviation database in consultedto see how many times it has happened. If the specified maximumnumber of repeats allowed has not been exceeded, the event stays inthe " Non-critical deviation" category (minor and major)Critical deviation: The event is plased in this category:>> When the answers given in the detection tree point to a "Criticaldeviation";>> If it was first classified as "Non-critical", but has exceeded themaxi mum nuber of repeats allowed.RESULTSIn range of one year, deviations are monitored and analyzed for med-ical device - X-ray films and concentrated solutions for haemodialysisin Production of medical devices in Alkaloid AD. Types of unconfor-mities for finished product X-ray films are classified in numerous cat-egories (a-m). Deviations are evaluated as incidents and non-critical(minor and major). Deviations considering monitoring of environmentconditions in production and storage area are classified as incidents.Deviations considering finished product X-ray films and concentratedsolutions for haemodialysis are classified as non-critical (minor andmajor). The applied actions usually decrease risk on acceptable level. There are corrective and preventive actions suitable for appropriatedeviations. These corrective actions contribute to the reduction orremoval of specified risk the consequences of the product and its ap-plication. The final approval of closed deviation is performed by Qual-ity Assurance before batch release of product.CONCLUSIONThis abstract describe the use of risk analysis tools for managingdeviations within the context of pharamceutical production. Thismethod involve using a decision diagram to classify deviations by theirimpact on product quality, based on definitions contained in ICH Q7A.By finally incorporating the information generated into the generalrisk anlysis for the process, knowledge of the process can be constantlyupdated in terms of:>> Critical points: redefining the control limits;>> Critical product quality attributes and how they relate theprocess parameters;>> Process capacity data;The effectiveness of actions within the CAPA system.283Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONThis approach enables deviations to be handled effectively, reducesthe resources needed by eliminating irrelevant incidents and givesproactive approach of continuous improvement. REFERENCES:ICH Q9, ICH Q10, ICH Q7AEC Directive 93/42/EEC of June 14,1993 and amended M521 CFR part 211 requirements regarding deviations and role of quality unitUPRAVUVANjE SO DEVIJATsII VOINTEGRIRANIOT SISTEM ZA KVALITETVO FARMATsIJATANada Popstefanova, Marija Davcheva, MiroslavaIlievska, Svetlana Trajkoska Dabevska, ALKALOID AD, SkopjeVOVEDOpshto, devijatsija (ostapuvanje) e neusoglasenost so vospostavenstandard. Vo Evropskiot vodich za Dobrata Proizvodna Praksa(DPP) se naveduva deka sekoe otstapuvanje od prifatenite baranjai postapki treba da bidat dokumentirani i objasneti.Integiraniot sistem za kvalitet vo farmatsijata se meri sporedreklamatsiite, devijatsiite, korektivni i preventivni merki iinspektsiski naodi. Obezbeduvanjeto na kvalitet treba da ginadmine nedostatotsite i da ja zgolemi vrednosta naorganizatsijata.TsELIsleduvanjeto na nedostatokot, devijatsijata i rezultatite nadvorod granitsite na spetsifikatsijata (OOS) vo farmatsevtskataindustrija e regulatorno baranje. Belezhenjeto na devijatsijata iisleduvanjeto na nejzinata prichina e eden chekor od ispolnuvanjetona regulatornite baranja. Ushte eden neopkhoden chekor ekoregiranje na naodot i zakluchok baziran na protsenka na rizikot,kako i razbiranje i utvrduvanje na korektivnite merki isproveduvanje na istite vo soodvetniot rok. Sproveduvanjeto namerkite treba da obezbedi deka istite se tselosni, efektivni ibez povtorno sluchuvanje na otstapuvanjeto, so shto se kompletiraaktivnosta. Tselosniot izveshtaj treba da bide razvien, pregledani odobren od Obezbeduvanje na kvalitet. Uspeshnoto odobruvanjena devijatsijata i OOS, kako i brojot/ udelot na devijatsii e kluchenindikator da se obezbedi tselosno integriran sistem za kvalitetvo farmatsijata, kako i nauchen pristap za postojano podobruvanjena kvalitetot.METODISledenjeto na protsesot, kvartalen pregled na site izveshtai odostapuvanjata kako i godishni pregledi na proizvodot seneopkhodnite alatki za odreduvanje deka negativnite trendovi nese razvivaat, a proizvodniot protses i ponatamu e pod kontrola.Upravuvanjeto so rizik se koristi za da se obezbedi postojansistem za donesuvanje odluki vrz osnova na nauchni i dokumentiranizapisi, so shto se ovozmozhuva odlukite da se potvrdat i predregulatornite tela. Upravuvanjeto so rizik kako alatka zaklasifikatsija i obrabotka na devijatsiite ovozmozheno e sodijagram na tek preku koj se donesuva odluka za kritichnosta nadevijatsijata. Vo primerot za meditsinski pomagala- rentgenfilmovi i kontsentrirani rastvori za khemodijaliza, protsesot vokoj se pojavuva devijatsijata e podlozhen na soodvetena rizikanaliza, pa poznati se slednive vidovi analizi:>> Istorija na devijatsijata povrzana so serioznosta naprifatliviot kriterium:>> Mozhnite podatotsi za najchestite nastanati devijatsii;>> Kritichnite tochki i /ili fazi od protsesot;>> Definitsija za kritichnite svojstva za kvalitetot naproizvodot;Upotrebenata metodologija sodrzhi nekolku fazi: analiziranje,klasifikatsija i obrabotka na devijatsijata.FAZA ZA ANALIZIRANjEtselta na ovaa faza e nastanot shto se sluchil da se klasifitsira vopredefinirana kategorija. Za taa tsel se koristi dijagram na tekbaziran na set od prashanja so da/ne odgovori, koi direktno jadefiniraat kategorijata na nastanot.FAZA ZA KLASIFITsIRANjEzemajkji ja vo predvid strategijata, nastanot se klasifitsira voedna od slednive kategorii: intsident, nekritchno ostapuvanje ikritichno ostapuvanje.FAZA NA OBRABOTKAvrz osnova na kategorijata vo koja e klasifitsiran nastanot, seprevzemaat slednive merki: Intsident: ako nastanot eklasifitsiran kako "Intsident" e zatvoren so opishuvanje namerkite potrebni za reshavanje na istiot. Nekritichni ostapuvanja:podatotsite za ostapuvanjeto na protsesot se zemaat predvid za da sevidi kolku pati se ima slucheno ostapuvanjeto. Ako se ushte ne enadminat dozvoleniot broj na povtoruvanja, nastanot ostanuva vokategorijata na nekritichni otstapuvanja (mali i pogolemi). Kritichni ostapuvanja: nastanot se vbrojuva vo ovaa kategorija:>> Koga odgovorite od dijagramot na odluchuvanje posochuvaat na"kritichna devijatsija">> Ako prvichno e kalsifitsiran kako "nekritichna", no gi imanadminato maksimalniot broj na povtoruvanja.REZULTATIVo ramkite od edna godina, sledeni i analizirani se devijatsiiteza meditsinskite pomagala - rentgen filmovi i kontsentriranirastvori za khemodijaliza vo Proizvodstvo na meditsinski pomagalavo Alkaloid AD. Tipovite na nesusoglasenosti za gotov proizvodna rentgen filmovi i kontsentrirani rastvori za khemodijaliza seklasifitsirani vo brojni kategorii (a-m). Devijatsiite se otsenetikako intsidenti i nekritichni (mali i pogolemi). Devijatsiite koi sevo vrska so uslovite na sredinata vo proizvodniot pogon i mestotona chuvanje se klasifitsirani kako intsidenti. Devijatsiite koi sevo vrska so gotoviot proizvod na rentgen filmovi i kontsen trir a -ni te rastvori za khemodijaliza se klasifitsirani kako nekritichni(mali i pogolemi). Sprovedenite merki voobichaeno go namaluvaatrizikot na prifatlivo nivo. Postojat korektivni i preventivnimerki pogodni za soodvetnite devijatsii. Ovie korektivni merkipridonesuvaat za namaluvanje ili ostranuvanje na odreden rizik zaproizvodot i negovata primena. Krajnoto odbruvanje nazatvorenata devijatsija ja vrshi Obezbeduvanje na kvalitet predosloboduvanje na serija proizvod.